Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Juan R. Luciano acquired 20 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Summary

• Juan R. Luciano, a director at Eli Lilly & Co, acquired 20 shares of common stock on February 20, 2024.
• The shares were acquired at a price of $755.66 each.
• This acquisition was made through the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Luciano's separation from service.
• Following this transaction, Mr. Luciano directly owns 15,612 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a routine transaction related to director compensation, indicating confidence in the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies like Eli Lilly.
• Many companies, such as Pfizer and Johnson & Johnson, offer similar deferral plans to their directors as part of their compensation packages.
• The price of $755.66 per share is consistent with the market price of Eli Lilly stock at the time of the transaction.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it reflects director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Form 4, Insider Trading